CRL Charles River Laboratories International Inc

Price (delayed)

$432.47

Market cap

$21.8B

P/E Ratio

54.47

Dividend/share

N/A

EPS

$7.94

Enterprise value

$24.54B

Charles River Laboratories, Inc., is an American corporation specializing in a variety of preclinical and clinical laboratory services for the pharmaceutical, medical device and biotechnology industries. It also supplies assorted ...

Highlights
The net income has increased by 46% year-on-year and by 6% since the previous quarter
The EPS rose by 44% YoY and by 5% QoQ
The price to earnings (P/E) is 76% higher than the 5-year quarterly average of 32.8 and 50% higher than the last 4 quarters average of 38.6
The quick ratio has declined by 31% since the previous quarter and by 27% year-on-year

Key stats

What are the main financial stats of CRL
Market
Shares outstanding
50.4M
Market cap
$21.8B
Enterprise value
$24.54B
Valuations
Price to earnings (P/E)
54.47
Price to book (P/B)
9.37
Price to sales (P/S)
6.64
EV/EBIT
41.26
EV/EBITDA
29.05
EV/Sales
7.5
Earnings
Revenue
$3.27B
EBIT
$594.85M
EBITDA
$844.92M
Free cash flow
$484M
Per share
EPS
$7.94
Free cash flow per share
$9.62
Book value per share
$46.14
Revenue per share
$65.08
TBVPS
$62.1
Balance sheet
Total assets
$6.72B
Total liabilities
$4.37B
Debt
$2.97B
Equity
$2.32B
Working capital
$338.3M
Liquidity
Debt to equity
1.28
Current ratio
1.36
Quick ratio
0.93
Net debt/EBITDA
3.25
Margins
EBITDA margin
25.8%
Gross margin
37.9%
Net margin
12.1%
Operating margin
16%
Efficiency
Return on assets
6.8%
Return on equity
18.6%
Return on invested capital
14.1%
Return on capital employed
10.3%
Return on sales
18.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CRL stock price

How has the Charles River Laboratories International stock price performed over time
Intraday
-5.64%
1 week
-0.13%
1 month
-0.98%
1 year
99.51%
YTD
73.08%
QTD
16.91%

Financial performance

How have Charles River Laboratories International's revenue and profit performed over time
Revenue
$3.27B
Gross profit
$1.24B
Operating income
$522.93M
Net income
$396.08M
Gross margin
37.9%
Net margin
12.1%
The net income has increased by 46% year-on-year and by 6% since the previous quarter
CRL's operating income is up by 40% YoY and by 13% QoQ
Charles River Laboratories International's gross profit has increased by 25% YoY and by 10% QoQ
Charles River Laboratories International's net margin has increased by 22% YoY

Growth

What is Charles River Laboratories International's growth rate over time

Valuation

What is Charles River Laboratories International stock price valuation
P/E
54.47
P/B
9.37
P/S
6.64
EV/EBIT
41.26
EV/EBITDA
29.05
EV/Sales
7.5
The price to earnings (P/E) is 76% higher than the 5-year quarterly average of 32.8 and 50% higher than the last 4 quarters average of 38.6
The EPS rose by 44% YoY and by 5% QoQ
The price to book (P/B) is 99% higher than the 5-year quarterly average of 5.0 and 53% higher than the last 4 quarters average of 6.5
The equity is up by 32% year-on-year and by 6% since the previous quarter
The P/S is 127% higher than the 5-year quarterly average of 3.1 and 53% higher than the last 4 quarters average of 4.6
CRL's revenue is up by 19% year-on-year and by 8% since the previous quarter

Efficiency

How efficient is Charles River Laboratories International business performance
The company's return on invested capital rose by 40% YoY
The ROS rose by 31% YoY
The company's return on assets rose by 24% YoY
The ROE has grown by 13% YoY

Dividends

What is CRL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CRL.

Financial health

How did Charles River Laboratories International financials performed over time
The company's total assets is 54% higher than its total liabilities
The quick ratio has declined by 31% since the previous quarter and by 27% year-on-year
The company's total assets rose by 28% YoY and by 16% QoQ
Charles River Laboratories International's debt is 28% higher than its equity
The equity is up by 32% year-on-year and by 6% since the previous quarter
Charles River Laboratories International's debt has increased by 25% QoQ and by 23% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.